trending Market Intelligence /marketintelligence/en/news-insights/trending/oPNJYZIDBT5OFrw8Tdtu1g2 content esgSubNav
In This List

Dr. Reddy's plaque psoriasis treatment secures US approval

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Dr. Reddy's plaque psoriasis treatment secures US approval

The U.S. Food and Drug Administration approved Dr. Reddy's Laboratories Ltd.'s new drug application for Impoyz cream for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older.

Impoyz is licensed to Encore Dermatology Inc. for commercialization of the product in the U.S.